CA
CRL icon

CoreCap Advisors’s Charles River Laboratories CRL Stock Holding History

CoreCap Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.03K Buy
31
+2
+7% +$356 ﹤0.01% 2191
2026
Q1 		$5K Hold
29
– – ﹤0.01% 2172
2025
Q4 		$5.79K Hold
29
– – ﹤0.01% 2154
2025
Q3 		$4.54K Hold
29
– – ﹤0.01% 2192
2025
Q2 		$4.4K Sell
29
-17
-37% -$2.27K ﹤0.01% 2146
2025
Q1 		$6.92K Buy
46
+1
+2% +$168 ﹤0.01% 1975
2024
Q4 		$8.31K Buy
45
+13
+41% +$2.5K ﹤0.01% 1844
2024
Q3 		$6.3K Buy
+32
New +$6.65K ﹤0.01% 1920
2024
Q2 		– Sell
-32
Closed -$8.67K – 1808
2024
Q1 		$8.67K Buy
+32
New +$7.64K ﹤0.01% 1776
2022
Q4 		$6.32K Buy
+29
New +$6.33K ﹤0.01% 1686
2022
Q3 		– Sell
-11
Closed -$2K – 843
2022
Q2 		$2K Buy
+11
New +$2.69K ﹤0.01% 1847
2022
Q1 		– Sell
-111
Closed -$42K – 855
2021
Q4 		$42K Buy
+111
New +$43.1K ﹤0.01% 1053

Other funds holding CRL

CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CPCPP
Canada Post Corporation Pension Plan Toronto, Canada $2.87B AUM 37.96% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
MPPW
Mitchell & Pahl Private Wealth Oklahoma City, Oklahoma $272M AUM 29.72% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

CoreCap Advisors's CRL Position: Q2 2026 in Review

CoreCap Advisors increased its Charles River Laboratories (CRL) stake by 6.9% in Q2 2026, buying an estimated $356 and bringing the position to 31 shares worth $7.03K. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

CoreCap Advisors first reported a position in CRL in Q4 2021 and has held it in 12 quarters since. The position peaked at $42K in Q4 2021. 62 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • CoreCap Advisors held 31 shares of Charles River Laboratories worth $7.03K as of Q2 2026.
  • CoreCap Advisors bought 2 Charles River Laboratories shares in Q2 2026, an estimated $356.
  • Charles River Laboratories made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2191 holding.
  • CoreCap Advisors first reported a position in Charles River Laboratories in Q4 2021 and has held it in 12 quarters since.
  • CoreCap Advisors's Charles River Laboratories position peaked at $42K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.